What Is the Treatment of Lymphocutaneous Sporotrichosis?

Lymphocutaneous sporotrichosis presents with a primary skin lesion and nodular involvement along regional lymphatic channels. This first-line protocol defines the treatment approach and the clinical endpoints that guide management.

Clinical Goals

Treatment targets clinical improvement of skin lesions — typically apparent within the first weeks of therapy — with eventual complete resolution of all active lesions as the primary endpoint.

Treatment Approach

First-line therapy consists of an oral antifungal agent, continued for a defined period beyond the point of full lesion clearance.

Specific agent, dosing strategy, and duration are detailed in the full structured protocol →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1086/522765

For cutaneous and lymphocutaneous sporotrichosis, itraconazole (200 mg orally daily) is recommended to be given for 2–4 weeks after all lesions have resolved, usually a total of 3–6 months (A-II).

Clinical improvement is often manifested within 4 weeks after starting therapy, and only a small number of patients need higher dosages of itraconazole or therapy with other antifungals.

View source ↗